Prognia
Drug Database
🇪🇺EU · EMALapsedATC: B01AC04

Clopidogrel Teva Generics B.V.(clopidogrel (as hydrochloride))

Peripheral Vascular Diseases;Acute Coronary Syndrome;Myocardial Infarction;Stroke

Marketing Authorisation Holder: Teva Pharma B.V.

EMA Authorisation: 28/10/2010

INN: clopidogrel

Indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. Patients suffering from acute coronary syndrome: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. For further information please refer to section 5.1.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Clopidogrel Teva Generics B.V. — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.